<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="811">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175693</url>
  </required_header>
  <id_info>
    <org_study_id>NB01S</org_study_id>
    <nct_id>NCT02175693</nct_id>
  </id_info>
  <brief_title>Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the clinical condition and safety in patients with cervical dystonia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Overall assessments of the improvement in the seriousness of seizures</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement is based on the 5 following elements: 1) Eminent improvement 2) Improvement 3) Improvement a little invariability 5) Exacerbation 6) It is not possible to judge</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>E2014</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cervical dystonia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with cervical dystonia

        Exclusion criteria:

        The patients who participated in this surveillance in the past
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akira Endo</last_name>
    <role>Study Director</role>
    <affiliation>Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Customer Information Services Department. CRC and QA</last_name>
    <email>_ML_CLNCL@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 20, 2015</lastchanged_date>
  <firstreceived_date>June 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Torticollis</keyword>
  <keyword>rimabotulinumtoxinB</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
